The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
NCT04432688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3192
Last updated 2024-04-18
Summary
It's a prospective, non-interventional, observational Post-marketing Surveillance..
Conditions
Interventions
- DRUG
-
Lurasidone HCl
This is a non-interventional, observational study
Sponsors & Collaborators
-
Sumitomo Pharma (Suzhou) Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Yifeng Xu · Shanghai Mental Health Center
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-01
- Primary Completion
- 2023-03-18
- Completion
- 2023-06-18
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
NCT05052853 ·Status: RECRUITING ·Phase: PHASE2
-
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
NCT03465787 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
NCT02202226 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
NCT05919823 ·Status: COMPLETED ·Phase: PHASE3
-
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
NCT04959201 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
NCT04510298 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia
NCT00810667 ·Status: COMPLETED ·Phase: PHASE2
-
Ginkgo Biloba Extract in the Treatment of Schizophrenia
NCT05258123 ·Status: COMPLETED ·Phase: NA
-
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
NCT04917302 ·Status: RECRUITING ·Phase: PHASE2
-
Sertindole in Asian Patients With Schizophrenia
NCT00864045 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia
NCT02021201 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
NCT00330226 ·Status: UNKNOWN
-
Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
NCT00063297 ·Status: COMPLETED ·Phase: PHASE2
-
Exploring the Effect of Rumination-Focused Cognitive Behaviour Therapy in Patients With Schizophrenia
NCT04442893 ·Status: COMPLETED ·Phase: NA
-
Metformin Treatment on Cognitive Impairment of Schizophrenia
NCT05838573 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy of Lu 31-130 in Patients With Schizophrenia
NCT00768326 ·Status: COMPLETED ·Phase: PHASE2
-
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
NCT00364429 ·Status: TERMINATED ·Phase: PHASE1
-
Berberine as Adjuvant Treatment for Schizophrenia Patients
NCT02983188 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Smartphone App on Medication Adherence
NCT05892120 ·Status: UNKNOWN
-
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
NCT03010865 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Antipsychotic Effects of Probiotics and Prebiotics on Patients With Schizophrenia
NCT04291469 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Mechanisms of Low-intensity Focused Ultrasound on Negative Symptoms in Patients With Schizophrenia
NCT04620460 ·Status: UNKNOWN ·Phase: NA
-
Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Patients With Schizophrenia
NCT00328952 ·Status: COMPLETED
-
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
NCT07230652 ·Status: RECRUITING ·Phase: PHASE1
-
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
NCT01234298 ·Status: WITHDRAWN ·Phase: PHASE3